An aptamer for recognizing the transmembrane protein PDL-1 (programmed death-ligand 1), and its application to fluorometric single cell detection of human ovarian carcinoma cells
- 2 August 2017
- journal article
- research article
- Published by Springer Nature in Microchimica Acta
- Vol. 184 (10) , 4029-4035
Abstract
No abstract availableKeywords
Funding Information
- Mashhad University of Medical Sciences (There is no specific grant number for this manuscript.)
This publication has 30 references indexed in Scilit:
- A review on amperometric immunoassays for tumor markers based on the use of hybrid materials consisting of conducting polymers and noble metal nanomaterialsMicrochimica Acta, 2017
- Advanced nanomaterials for use in electrochemical and optical immunoassays of carcinoembryonic antigen. A reviewMicrochimica Acta, 2017
- PD-1/PD-L1 inhibitorsCurrent Opinion in Pharmacology, 2015
- PD-L1 Expression as a Predictive Biomarker in Cancer ImmunotherapyMolecular Cancer Therapeutics, 2015
- B7-H1/PD-1 Blockade Therapy in Non–Small Cell Lung CancerThe Cancer Journal, 2014
- Immune checkpointsOncoImmunology, 2014
- Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancersCancer Immunology, Immunotherapy, 2006
- Tumor B7-H1 Is Associated with Poor Prognosis in Renal Cell Carcinoma Patients with Long-term Follow-upCancer Research, 2006
- B7-H1 Expression on Non-Small Cell Lung Cancer Cells and Its Relationship with Tumor-Infiltrating Lymphocytes and Their PD-1 ExpressionClinical Cancer Research, 2004
- PD-1:PD-L inhibitory pathway affects both CD4+ and CD8+ T cells and is overcome by IL-2European Journal of Immunology, 2002